P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS

• J.-M. Sancho,
• A. Lopez-Guillermo,
• P. Abrisqueta,
• A. Kumar,
• R. Cordoba,
• M. Tani,
• W. Zhao,
• E. Rappold,
• P. Langmuir,
• M. Mims

Affiliations

J.-M. Sancho

1 Clinical Hematology Department, Hospital Germans Trias i Pujol, Institut Català d’Oncologia

A. Lopez-Guillermo

2 Clinic Barcelona

P. Abrisqueta

3 Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain

A. Kumar

4 University of Arizona, Tucson, United States of America

R. Cordoba

5 Lymphoma Unit, Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

M. Tani

6 Haematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy

W. Zhao

7 Incyte Corporation, Wilmington

E. Rappold

7 Incyte Corporation, Wilmington

P. Langmuir

7 Incyte Corporation, Wilmington

M. Mims

8 Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, United States of America